21 CFR 820.80
Lack of or inadequate final acceptance procedures
- Inspections citing it: 2,524
- Of those classified, ended OAI: 24%
- Last cited: FY2026
Inspections Citing It by Fiscal Year
Sites in and outside the US, FY2017 to Oct 20, 2026.
Paragraphs Cited
As FDA posts them, all years.
- 820.80(d)
- 669 · Lack of or inadequate final acceptance procedures
- 820.80(b)
- 660 · Lack of or inadequate receiving acceptance procedures
- 820.80(a)
- 559 · Lack of or inadequate procedures - Acceptance activities
- 820.80(e)
- 352 · Documentation
- 820.80(c)
- 261 · Lack of or inadequate In-process acceptance procedures
- 820.80(d)(3)
- 9 · No release signature
- 820.80(d)(1)
- 7 · DMR required activities {see also 820.181}
- 820.80(d)(2)
- 7 · Review of data and documentation
Regulation Text
eCFR did not answer; open it on eCFRRecently Cited Sites
Newest inspections citing this section; each opens the site- Innova Vascular IncUnited States · Jan 12, 2026
- Osseofuse International Inc.United States · Jan 7, 2026
- Peter Schiff EnterprisesUnited States · Dec 31, 2025
- DiAgam Societe Anonyme (S.A.)Belgium · Dec 18, 2025
- My Medical Store LLCUnited States · Dec 18, 2025
- Mercury Enterprises, Inc.United States · Dec 11, 2025
- Specialty Health Products CO, LLCUnited States · Dec 11, 2025
- Avokaid, LLCUnited States · Nov 25, 2025
- 3D Diagnostix Inc.United States · Nov 21, 2025
- Pathright Medical IncUnited States · Nov 17, 2025
- Akervall Technologies, Inc.United States · Nov 6, 2025
- Splintek, IncUnited States · Oct 30, 2025
Counts are inspections with posted citations that cite any paragraph of the section, once per inspection, from FDA's Data Dashboard. OAI share is over inspections FDA finally classified. Text from eCFR, the official online CFR. FDA Data Dashboard and eCFR